These five genes (PDGFRA, PTGS2, MMP9, MAPK1, and MET) have been recognized as the target of andrographolide that has an association with CRC, thus making them the most reliable genes that can be used in clinical settings. This evidence concerns the gene MMP9 and colorectal carcinoma.